Group 1 - The core product ABSK021 has received approval from NMPA for the treatment of symptomatic adult TGCT patients, marking it as the first self-developed drug for this condition in China [1][2] - The successful approval of ABSK021 signifies the company's transition from clinical research to commercialization, validating its full-cycle innovation capability from target selection to market approval [2][3] - Long-term follow-up data indicates that the response rate for patients treated with ABSK021 improves over time, with a reported overall response rate (ORR) of 76.2% at a median follow-up of 14.3 months in the Phase III trial [3] Group 2 - The collaboration with Merck is expected to enhance the commercial potential of ABSK021, providing a stable cash flow for the company [1][3] - The successful launch of ABSK021 is anticipated to significantly contribute to the company's revenue, especially given the lack of suitable innovative therapies for TGCT [3]